Investors
About NeuroSense
NeuroSense Therapeutics is a clinical-stage drug development company, advancing a groundbreaking treatment for people with ALS, as well as other neurodegenerative diseases. We are focused on creating a combined therapeutic strategy, targeting the multiple pertinent mechanisms in these complex diseases.
PrimeC, our lead therapeutic candidate for ALS, has been granted orphan drug designation by the FDA and EMA, and has been tested successfully in a phase 2a study. Preparations are underway for a pivotal phase II/3 clinical trial in ALS.
Additionally, we are currently expanding our pipeline and are initiating preclinical studies in additional neurodegenerative indications for PrimeC.
We invite you to take part in our program and accelerate the clinical development toward a cure for ALS and other neurodegenerative diseases.
Investment in NeuroSense
To date, there is no effective drug for ALS. The available treatments in the market can slightly moderate disease progression, or delay death by only a few months.
NeuroSense’s drug in development, PrimeC, targets multiple pathological mechanisms simultaneously and works synergistically to slow and perhaps halt disease progression.
We welcome you to contact below or call us at: +972-587-531153
Key Investment Merits
Short Time to Market, and Known Safety Profiles
Excellent ALS Pre-clinical Results
Promising Clinical Trends in ALS Patients
Bright and Passionate Minds Motivated to the Cause
Non-invasive Treatment
Addressing Several Pertinent Targets
Further Neurodegenerative Indications
Orphan Drug Incentives
Why Invest in NeuroSense?
- PrimeC has shown outstanding results in preclinical models of ALS compared with current FDA-approved drug Riluzole, and it has been tested successfully in a phase 2a study in patients with ALS.
- PrimeC uses a novel formulation of unique doses of two FDA-approved drugs with well-known safety profiles to target the multiple pathological pathways of ALS. As a result, we expect that the drug should be available for patients within a relatively short time after clinical testing is complete.
- The dedicated and experienced team is working relentlessly to make an effective drug available within four years.
- The FDA has granted PrimeC an orphan drug designation from FDA and EMA, allowing 7 and 10 years of market exclusivity, respectively, as well as conferring financial grants and tax benefits upon commercialization.
- Preclinical studies have been expanded into additional neurodegenerative diseases.
- NeuroSense has collaborative relationships with world-renowned institutes to expedite the execution of research and clinical trials.
Market and Competition
The market for an effective drug that can stop or significantly slow ALS disease progression is estimated at billions of dollars. There are an estimated 70,000 ALS patients in the western world, and 450,000 patients worldwide. The average cost per year for patients in the U.S. in late stages of the disease are estimated at $300,000.
Several other companies are at different stages of drug development for ALS. These include: Cytokinetics, Biogen, AB Science, Kadimastem, Immunity Pharma and Amylyx.
Disease Modifying Treatment vs. Symptomatic Treatment
Many of the available drugs and treatments in development today for ALS address merely the symptoms of the disease, and grant patients only a few extra months of functionality. NeuroSense’s novel drug aims to drastically slow or even halt disease progression, hence increasing patients’ life expectancy and improving quality of life.
Molecular Mechanisms vs. Stem Cells
In contrast to other companies, which focus on stem cell treatments aimed at affecting the system as a whole, NeuroSense emphasizes the multifarious underlying pathological and molecular mechanisms of the disease in order to pinpoint the treatment effect.
Pain-Free vs. Invasive Treatment
Many of the treatments being developed for ALS patients are invasive, and include extraction and/or injection of cells or other types of infusions. NeuroSense’s drug is a small, easy-to-use pill to be swallowed.
Join Our Newsletter
